» Articles » PMID: 33387530

Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis

Abstract

Background & Aims: To influence host and disease phenotype, compositional microbiome changes, which have been demonstrated in patients with primary sclerosing cholangitis (PSC), must be accompanied by functional changes. We therefore aimed to characterize the genetic potential of the gut microbiome in patients with PSC compared with healthy controls (HCs) and patients with inflammatory bowel disease (IBD).

Methods: Fecal DNA from 2 cohorts (1 Norwegian and 1 German), in total comprising 136 patients with PSC (58% with IBD), 158 HCs, and 93 patients with IBD without PSC, were subjected to metagenomic shotgun sequencing, generating 17 billion paired-end sequences, which were processed using HUMAnN2 and MetaPhlAn2, and analyzed using generalized linear models and random effects meta-analyses.

Results: Patients with PSC had fewer microbial genes compared with HCs (P < .0001). Compared with HCs, patients with PSC showed enrichment and increased prevalence of Clostridium species and a depletion of, for example, Eubacterium spp and Ruminococcus obeum. Patients with PSC showed marked differences in the abundance of genes related to vitamin B6 synthesis and branched-chain amino acid synthesis (Q < .05). Targeted metabolomics of plasma from an independent set of patients with PSC and controls found reduced concentrations of vitamin B6 and branched-chain amino acids in PSC (P < .0001), which strongly associated with reduced liver transplantation-free survival (log-rank P < .001). No taxonomic or functional differences were detected between patients with PSC with and without IBD.

Conclusions: The gut microbiome in patients with PSC exhibits large functional differences compared with that in HCs, including microbial metabolism of essential nutrients. Alterations in related circulating metabolites associated with disease course, suggesting that microbial functions may be relevant for the disease process in PSC.

Citing Articles

Primary sclerosing cholangitis.

Manns M, Bergquist A, Karlsen T, Levy C, Muir A, Ponsioen C Nat Rev Dis Primers. 2025; 11(1):17.

PMID: 40082445 DOI: 10.1038/s41572-025-00600-x.


Treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: a comprehensive review.

Villard C, Jorns C, Bergquist A eGastroenterology. 2025; 2(1):e100045.

PMID: 39944751 PMC: 11770459. DOI: 10.1136/egastro-2023-100045.


Sometimes Small Is Beautiful: Discovery of the Janus Kinases (JAK) and Signal Transducer and Activator of Transcription (STAT) Pathways and the Initial Development of JAK Inhibitors for IBD Treatment.

Kaunitz J Dig Dis Sci. 2025; .

PMID: 39827247 DOI: 10.1007/s10620-024-08791-1.


Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.

Sannaa W, Almasry M, Peedikayil M, Grimshaw A, Attamimi M, AlMutairdi A Therap Adv Gastroenterol. 2025; 18:17562848241312766.

PMID: 39802627 PMC: 11719443. DOI: 10.1177/17562848241312766.


Management of primary sclerosing cholangitis: Current state-of-the-art.

Cancado G, Hirschfield G Hepatol Commun. 2025; 8(12).

PMID: 39774274 PMC: 11567710. DOI: 10.1097/HC9.0000000000000590.


References
1.
Midttun O, Hustad S, Ueland P . Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009; 23(9):1371-9. DOI: 10.1002/rcm.4013. View

2.
Magnusdottir S, Ravcheev D, de Crecy-Lagard V, Thiele I . Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. Front Genet. 2015; 6:148. PMC: 4403557. DOI: 10.3389/fgene.2015.00148. View

3.
Schrumpf E, Kummen M, Valestrand L, Greiner T, Holm K, Arulampalam V . The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation. J Hepatol. 2016; 66(2):382-389. PMC: 5250551. DOI: 10.1016/j.jhep.2016.09.020. View

4.
Vesterhus M, Hov J, Holm A, Schrumpf E, Nygard S, Godang K . Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology. 2015; 62(1):188-97. DOI: 10.1002/hep.27825. View

5.
Muller N, Schulte D, Turk K, Freitag-Wolf S, Hampe J, Zeuner R . IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res. 2015; 56(5):1034-42. PMC: 4409280. DOI: 10.1194/jlr.P052209. View